ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SCTB39-1

A development code. Also written as “SCTB41+SCTB39-1”.

Its studies are led by Sinocelltech Group.

Furthest: phase 2, since Jun 25, 20252 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinocelltech Group22 open or runningphase 2since Jun 25, 2025Jun 25, 2025Jun 30, 2028phase 2 · NCT07050641

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 25, 2025First study: phase 2 study in Advanced Malignant Solid TumorFirst studyNCT07050641 · 110 planned · China
  2. May 11, 2026Phase 2 study in Advanced Malignant Solid TumorNCT07594028 · 126 planned

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07050641
  2. May 30, 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07594028

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07594028Advanced Malignant Solid Tumor2Not yet recruitingMay 30, 2029126
NCT07050641Advanced Malignant Solid Tumor · China2RecruitingJun 30, 2028110

How it is read

Names in the registry

  • “SCTB41+SCTB39-1”, 1 entry
  • “SCTB39-1”, 1 entry

Codes read as this program: SCTB391.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.